You need to enable JavaScript to run this app.
Recon: Blueprint's $250M preclinical buy; WHO, CDC, Biden react to Omicron variant
Recon
Kari Oakes
APIs
Biologics
Biotechnology
Combination Products
Diagnostics
Global
Medical Devices
Pharmaceuticals